• Structure Therapeutics released a presentation outlining updates on its oral obesity pipeline, highlighting ACCG-2671 as an oral amylin candidate.
• Slides also flagged progress on aleniglipron, citing completion of the ACCESS 72-week open-label extension and a Phase 3 update.
• Materials framed a large under-treated obesity market, estimating 3 billion people overweight or obese globally versus about 11-13 million on branded anti-obesity drugs.
• Presentation cited rapid uptake of oral GLP-1s in the U.S., estimating more than 1.4 million patients on oral GLP-1 therapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.